System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish

PubMed: 40167033 DOI: 10.1002/cbdv.202403401

Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition.

Chem Biodivers 22(8):e202403401

Authors: Najlaa Hamed Almohmadi, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Ali K Albuhadily, Morkoss M Fakhry, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batiha

Affiliations

  • Clinical Nutrition Department, College of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
  • Jabir Ibn Hayyan Medical University, Kufa, Iraq.
  • Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.
  • University Centre for Research & Development, Chandigarh University, Chandigarh-Ludhiana Highway, Mohali, Punjab, India.
  • Department of Research & Development, Funogen, Athens, Greece.
  • University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany.
  • Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.

Abstract

Alzheimer's disease (AD) is the main cause of dementia worldwide. AD is a progressive brain neurodegenerative disease due to genetic and environmental factors that induce a progressive accumulation of intracellular hyperphosphorylated tau protein and extracellular amyloid protein (Aβ). However, anti-AD medications cannot reverse the fundamental AD neuropathology due to amyloid plaques and related oxidative stress and inflammatory reactions. Thus, targeting other pathways might be reasonable in the management of AD. The serotonin (5-HT) neurotransmitter plays a crucial role in preventing neurodegeneration and related oxidative stress and inflammatory reactions. In addition, the serotonergic system is highly dysregulated in many neurodegenerative diseases, including AD. Deregulation of serotonin synthesis and its receptors is involved in the pathogenesis of AD. Therefore, this review aims to discuss how the serotonergic system is affected in AD, and how 5-HT modulators can reverse AD neuropathology and alleviate the associated neuropsychiatric disorders in AD patients.

MeSH

Biochemistry, Alzheimer Disease, Stress, Physiological, Oxidative Stress, Serotonin, Amyloid, Neuropathology, Neurodegenerative Diseases